SciSparc subsidiary NeuroThera raises C$5.4 million in private placement financing

SciSparc Ltd. (Nasdaq: SPRC) said on August 18, 2026 that its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.¹

SciSparc participated in the financing with a C$2.7 million investment, representing 50% of the total gross proceeds raised.¹ SciSparc subscribed for 22,500,000 units priced at C$0.12 each, with each unit made up of one NeuroThera common share plus one common share purchase warrant.¹

The warrants run for three years and carry an acceleration provision: if NeuroThera's securities are approved for trading on the Nasdaq Stock Market, the expiry date for half of the unexercised warrants will be moved up, with NeuroThera required to give three business days' written notice to warrant holders ahead of that accelerated date.¹

After the financing, SciSparc holds approximately 44.6% of NeuroThera's issued and outstanding common shares, and the company put the value of that stake at approximately C$30 million.¹ NeuroThera said it plans to use the net proceeds for general working capital and other corporate and administrative expenses.¹

According to the filing's corporate description, SciSparc, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical development, with a focus on cannabinoid-based technologies and assets.¹ The two companies together are developing SCI-110 for Tourette syndrome and for Alzheimer's disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus, both based on THC and/or non-psychoactive CBD.¹

The underlying agreement was dated August 13, 2026, with the transaction closing on August 15, 2026, according to the Form 6-K.